Sentences with phrase «patients after chemotherapy»

Not exact matches

«More than twice the number of patients [were] still living at the end of the study after receiving IMAB362 plus chemotherapy compared to chemotherapy alone,» according to Ganymed CEO Özlem Türeci, with patients showing the highest level of that protein biomarker responding best to the treatment.

VICTORIA — A plan to cut chemotherapy services for cancer patients in Nanaimo that was reversed only after public outcry shows B.C. Liberal cuts are leading to bad policy decisions that will hurt patients, say New Democrats.

The targeted radiotherapy shrank tumors for 71 % of patients who had already failed standard chemotherapy, but these results came from a small trial that started with 30 patients and then added another 20 after positive data started rolling in.

After the patient has returned home from the hospital, the next stage of treatment is consolidation, in which patients receive several additional rounds of chemotherapy to build upon the effects of induction.

A patients» tumors from cholangiocarcinoma, a rare liver cancer that typically fails chemotherapy, shrunk significantly after treatment with FGFR inhibitors, which were prescribed based on results of next generation sequencing.

Approximately one year after successful treatment with cytotoxic chemotherapy and radiotherapy, patients with advanced Small Cell Lung Cancer (SCLC), which primarily affects heavy smokers, generally relapse with recurrence of tumours that are resistant to further chemotherapy.

Results of the trial, reported in the May 31 issue of the New England Journal of Medicine and presented at the American Society for Clinical Oncology 2015 annual meeting, also showed that after a year, the nivolumab group had nearly double the survival rate (42 percent) of the chemotherapy patients (24 percent).

Seventeen patients received GO alone when MRD was detected after two rounds of chemotherapy with the drugs cytarabine, daunorubicin and etoposide.

Patients with metastatic non-small cell lung cancer will always progress after chemotherapy, so most patients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fightPatients with metastatic non-small cell lung cancer will always progress after chemotherapy, so most patients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fightpatients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fight cancer.

A majority of patients (80 %) experience a relapse after their initial treatment with chemotherapy, therefore a more effective line of treatment is needed.

In a clinical trial published in June, melanoma patients who received ipilimumab combined with chemotherapy gained a precious extra few months» survival compared with those who received chemo alone, and the treatment nearly doubled the number of patients still living after three years.

Dr. Rassool says that a clinical trial is planned to test whether low doses of a DNMT inhibitor, decitabine, and an investigational PARP inhibitor, talazoparib, can be safely combined and whether this therapy shows efficacy for AML patients, especially those who can not receive intensive chemotherapy, whose leukemia is resistant to treatment, or who have experienced a relapse after treatment.

Patients receive cyclophosphamide for two days after their bone marrow transplant, in addition to two other chemotherapy drugs given before the transplant.

The researchers then compared the images with the patients» outcomes after five months of chemotherapy.

During and after chemotherapy, many cancer patients describe feeling a mental fog, a condition that has been dubbed «chemo brain.»

A team of researchers at Ligand Pharmaceuticals in San Diego and SmithKline Beecham Pharmaceuticals in Collegeville and King of Prussia, Pennsylvania, wanted to find a mimic of granulocyte - colony - stimulating factor (G - CSF), which is commonly used to boost patients» immune systems after chemotherapy.

The researchers analyzed the samples using immunohistochemistry and RNA sequencing to study the changes in the tumor immune microenvironment of patients who received and did not receive chemotherapy, and changes before and after chemotherapy.

Many cancer patients that receive chemotherapy go into remission at first, but relapse after treatment is discontinued.

A drug recently developed by Pfizer, crizotinib, targets ALK and is currently given to patients with ALK positive lung cancer when their cancer has worsened after initial chemotherapy.

They found that it took longer for the disease to progress in patients whose tumour DNA count in the blood fell by more than a half after one cycle of chemotherapy, compared with patients whose DNA count did not drop.

For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression - free survival, researchers report at the ESMO 2014 Congress in Madrid.

Patients in clinical remission — whose tumors have disappeared or are significantly reduced in size — are given a course of immune treatment after a six - month rest period following chemotherapy.

At Colchester General Hospital, the researchers looked at MR scans taken both before treatment and six weeks after the patients had completed chemotherapy and radiotherapy, and found that the patients whose tumors were less heterogeneous — ie more uniform — in terms of texture parameters six weeks after treatment were more likely to survive longer.

Appearing in Lancet Oncology, long term results of EORTC trial 22921 with 10.4 years median follow - up show that 5 - FU (fluorouracil) based adjuvant chemotherapy after preoperative (chemo)- radiotherapy for patients with cT3 - resectable T4 M0 rectal cancer does not improve survival or disease - free survival.

After the neo-adjuvant chemotherapy, the patients were then given accelerated radiotherapy.

After chemotherapy, as many as 65 per cent of patients with breast cancer report memory lapses, difficulty concentrating, taking longer to complete tasks and difficulty multitasking.

Treating patients with high - dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid.

Our system will give patients continual support both during and after chemotherapy, while allowing them to remain in the comfort of their own homes.

If it proves as effective in people as it is in mice, a vaccine could one day be given to cancer patients after surgery, radiation therapy, or chemotherapy to prevent tumors from regrowing.

Many tumor patients are consequently treated with chemotherapy after surgery to fight metastasis.

Three of the patients did not complete chemotherapy — one died after consent but prior to chemotherapy; one died during chemotherapy because of an arterial occlusion; and one had a myocardial infarction prior to completion of the four courses of chemotherapy.

In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine - based induction chemotherapy, and assessed the effect of erlotinib on survival.

At Colchester General Hospital, the researchers looked at MR scans taken both before treatment and six weeks after the patients had completed chemotherapy and radiotherapy, and found that the patients whose tumours were less heterogeneous — ie more uniform - in terms of texture parameters six weeks after treatment were more likely to survive longer.

THREE patients with incurable neck and head cancer have survived for three years after being treated with a combination of chemotherapy and a cold virus that has been modified to attack tumours.

Clinicians have historically been hesitant to treat HIV patients with stem cell transplant due to concerns that their immune systems would not effectively recover after intensive chemotherapy or that the procedure would cause excessive toxicities or infections post-transplant.

In nonmetastatic triple - negative breast cancer (TNBC) patients, we investigated whether circulating tumor DNA (ctDNA) detection can reflect the tumor response to neoadjuvant chemotherapy (NCT) and detect minimal residual disease after surgery.

Each of the patients underwent tumor biopsies before, during, and after a 20 - week regimen of chemotherapy.

A Randomized, Double - Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First - line Chemotherapy in Patients with Metastatic Urothelial Cancer

The study included 44 patients in the sunitinib group and 41 patients in the placebo group; all received a chemotherapy regimen of cisplatin or carboplatin and etoposide after enrollment but prior to randomization.

Some patients will receive chemotherapy after surgery to help treat any cancer cells that went undetected and therefore could not be removed during surgery.

Platinum - sensitive ovarian cancer patients with a positive predictive AGO score who undergo a secondary debulking surgery after relapse on platinum chemotherapy experience longer progression - free survival.

FLT3 mutations are more common in patients with normal karyotype and appear to be associated with a higher rate of relapse after conventional chemotherapy.

Pair of sequential virus isolates from a patient with ARC / AIDS taken at 0 (A018A) and 14 (A018C) months after commencing AZT chemotherapy.

Two main examples of these translational studies we participated on can be exposed: The first Cog - Age clinical study (Pr F. Joly, Baclesse Caen) showed that cognitive decline can be detected 6 months after chemotherapy in breast cancer elderly patients.

Patients with ER - negative, but not ER - positive, isolated locoregional recurrence after unilateral breast cancer derive significant benefit from chemotherapy.

To assess these responses in well defined cohorts of M. tuberculosis - infected or exposed individuals and patients with active TB either or not co-infected with HIV, and follow up longitudinally after anti-tuberculosis chemotherapy, in order to correlate specific responses with protective immunity.

Investigators led by Edward S. Kim, MD, of MD Anderson Cancer Center in Houston, initiated the SELECT trial after earlier, phase II studies showed that cetuximab improved response rates when added to chemotherapy regimens for patients with recurrent or progressive NSCLC.

[iv] Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open - label, phase 3 trial.

Patients with stage - IV cancer with one to five distant metastases and no tumors bigger than 10 centimeters (about four inches) in diameter were eligible to participate in the study either before or after chemotherapy treatment.

The trial actually enrolled 938 patients with recurrent advanced NSCLC; physicians initially chose pemetrexed or docetaxel for patients, after which patients were randomized to either chemotherapy alone or in addition to a cetuximab regimen.